Active-control study to evaluate the safety, tolerance and immunogenicity of Fluviral S/F influenza vaccine in healthy adults aged 18-64 years of age

Trial Profile

Active-control study to evaluate the safety, tolerance and immunogenicity of Fluviral S/F influenza vaccine in healthy adults aged 18-64 years of age

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs GSK 1536489A (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jul 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 07 Jul 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 03 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top